DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Methylene Blue in Sepsis: A Randomized Controlled Trial

Information source: Queen's University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sepsis

Intervention: methylene blue (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: Queen's University

Official(s) and/or principal investigator(s):
Daniel W Howes, MD, Principal Investigator, Affiliation: Queen's University


The purpose of this study is to investigate whether the addition of Methylene Blue to the standard treatment of septic shock will reduce vasopressor requirements

Clinical Details

Official title: Intermittent Bolus Infusion of Methylene Blue to Reduce Norepinephrine Requirements in Sepsis: A Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary outcome of interest is to assess the norepinephrine requirements in the methylene blue groups to maintain a mean arterial blood pressure greater or equal to 65 mmHg in comparison to the control group.

Secondary outcome:

safety of methylene blue

survival to ICU discharge

survival to hospital discharge

total norepinephrine administered

number of whole hours norepinephrine free

Detailed description: The management of severe infections, sepsis and septic shock is a serious problem facing physicians. Septic shock kills 10,000 Canadians every year. It is the most common cause of death in intensive units and the rates of sepsis and septic shock continue to increase annually. Septic shock is a complex interaction between pathologic vasodilation, relative and absolute hypovolemia, myocardial depression, and altered microvascular function resulting from a systemic inflammatory response to infection. After restoration of the circulating volume, many patients continue to suffer from a maldistribution of blood flow. Current hypotheses suggest that global indicators of hypoperfusion (serum lactate, hypotension, decreased oxygen delivery) represent an averaging of areas of normal or increased blood flow with areas where blood flow is decreased. These under-perfused areas become more hypoxic. The resulting tissue damage leads to more inflammation and more maldistribution, perpetuating a vicious cycle progressing on to death. Vasopressive agents are used in an attempt to maintain mean arterial blood pressure and restore perfusion, but these agents work globally, potentially worsening blood flow to the under-perfused areas. As well, many vasopressors have deleterious side effects such as metabolic and endocrine functions, and changes to regional blood flow. The microvascular changes are mediated by primarily nitric oxide (NO). Baseline levels of nitric oxide are produced by constitutive Nitric Oxide Synthase (cNOS), with NO levels measured in the nano-molar range. Inflammatory mediators cause increased production of inducible Nitric Oxide Synthase (iNOS) leading to NO levels measured in the micro-molar range. Suppression of nitric oxide production using non-specific NOS inhibitors has had discouraging results. Methylene Blue is a selective iNOS inhibitor. The purpose of this pilot study is to confirm safety and demonstrate signs of benefit in the use of methylene blue in sepsis. In particular, this study will examine whether the addition of methylene blue to standard early goal directed therapy in sepsis will reduce vasopressor requirements.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- First presentation of sepsis syndrome: clinical evidence of infection with Systemic

Inflammatory Response Syndrome (SIRS)as defined by two or more of:

- Temperature > 38°C or < 36°C,

- Heart rate > 90 beats per minute,

- One or more of respiratory rate > 20, hyperventilation with PaCO2 < 32 mm Hg,

requiring mechanical ventilation,

- One or more of white blood cells > 12,000 X 109 /L or white blood cells < 4000

X 109 /L or immature neutrophils > 10%.

- Undergoing early goal directed therapy with a mean arterial blood pressure (MAP) < 65

mmHg despite fluid resuscitation to CVP > 10mmHg.

- Able to provide informed consent as per our institutional standard.

- To receive first dose of study drug within six hours of first recorded hypotension

(MAP < 65mmHg). Exclusion Criteria:

- Age < 18 years.

- Undergoing palliation.

- Not expected to survive 48 hours.

- Resuscitated from a vital sign absent arrest.

- Ongoing dialysis.

- Anuric or creatinine > 300 μmol/L.

- Pregnant.

- Patient or family history of glucose-6-phosphate dehydrogenase deficiency.

- Allergic to methylene blue, phenothiazines, thiazide diuretics, or food dyes.

- Patient mass > 150 kg.

- Demonstrated Pulmonary Hypertension (Mean Pulmonary Artery Pressure > 25 mmHg by

Swan Ganz Catheter or Echo demonstrated Right Ventricular Systolic Pressure > 40 mmHg).

Locations and Contacts

Additional Information

Starting date: June 2007
Last updated: May 26, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017